Building off a highly successful inaugural year, CDRD, Canada’s life sciences venture, is proud to open applications to its 2019-2020 Executive Institute – a 10-month, highly-focused executive development program custom-designed to grow and nurture the management talent that the Canadian life sciences sector needs to lead the world.
By combining TRIUMF’s expertise in manufacturing isotopes and radiolabelling conjugates with CDRD’s ability to identify and validate potential biological targets to develop therapeutic agents such as monoclonal antibodies, new “weaponized targeted therapies” can be created for the treatment of cancers with significant unmet medical need. In doing so, the organizations are leveraging two of Canada’s complementary national strengths to create a unique global competitive advantage; while also enabling an integrated health sciences ecosystem that bridges the gap between academic research, commercialization, and patient care in targeted alpha therapeutics.
CDRD is a proud sponsor of the TAT11 International Symposium on targeted alpha therapy hosted by Canadian Nuclear Laboratories. We are excited to be co-hosting a panel discussion “The Renaissance…
This new investment will enable Sitka and its partner Cancer Research UK (CRUK) to accelerate critical development activities and rapidly enter clinical trials of STK-01, Sitka’s lead product for the treatment of bladder cancer.
Vancouver, Canada: CDRD, Canada’s national life sciences venture, is pleased to announce the appointments of Ms. Wendy Hurlburt and Mr. William Charnetski as new Directors of the organization. Wendy Hurlburt,…
CDRD has been selected for a Science Co-op Employer Recognition Award by the University of British Columbia (UBC). In addition, two of CDRD’s employees: David Shin, Data Integrity Manager and Eric Cruz, Associate Scientist in Biologics, have also been selected to receive Supervisor Awards.
On World Diabetes Day, Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is raising awareness about hypoglycemia (low blood sugar) that can cause serious complications and even death for people with diabetes.
To exemplify the collaborative spirit and leadership needed to advance the Canadian health and biosciences sector, Canadian life sciences leaders – CDRD, LifeSciences BC, TRIUMF Innovations and BIOTECanada – are hosting an event today to build support and encourage action and agreement that will advance recommendations from The Government of Canada’s Health and Biosciences Economic Strategy Table Report.
Through this new structure, CDRD will be even stronger, and seek to realize our vision of Canadian life sciences leading the world.
Didier is at the forefront of life sciences investment in Canada, working with the Fonds de solidarité FTQ on a mission that is perfectly aligned with CDRD’s, to contribute to Québec’s and Canada’s economic growth by creating jobs through investments in small and medium-sized businesses, helping them scale up to be new life sciences anchor companies.